专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010151526A1 BISPECIFIC ANTIBODIES THAT BIND TO COMPLEMENT PROTEINS 审中-公开
标题翻译：双重补充蛋白质的双重抗体
公开(公告)号：WO2010151526A1
公开(公告)日：2010-12-29
申请号：PCT/US2010/039448
申请日：2010-06-22
申请人： ALEXION PHARMACEUTICALS, INC. , TAMBURINI, Paul, P.
发明人： TAMBURINI, Paul, P.
IPC分类号： C07K16/46 , A61P31/00 , C07K16/18 , A61K39/00
CPC分类号： C07K16/2896 , C07K16/18 , C07K2317/31 , C07K2317/94
摘要： The present disclosure relates to bispecific antibodies that can bind to two or more different epitopes. For example, the bispecific antibodies described herein can bind to two or more different proteins, wherein at least two of the proteins are selected from C5a, C5b, a cellular receptor for C5a (e.g., C5aR1 or C5L2), the C5b-9 complex, and a component or intermediate of terminal complement such as C5b-6, C5b-7, or C5b-8. The bispecific antibodies described herein are useful for, e.g., inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 complex) and/or C5a anaphylatoxin-mediated inflammation (e.g., C5a-mediated chemotaxis of inflammatory immune cells). Accordingly, the bispecific antibodies can be used in methods for treating a variety of complement pathway-associated disorders.
摘要翻译：本公开涉及可以结合两个或多个不同表位的双特异性抗体。例如，本文所述的双特异性抗体可以结合两种或更多种不同的蛋白质，其中至少两种蛋白质选自C5a，C5b，C5a的细胞受体（例如C5aR1或C5L2），C5b-9复合物，和末端补体的成分或中间体如C5b-6，C5b-7或C5b-8。本文所述的双特异性抗体可用于例如抑制末端补体（例如，C5b-9复合物的组装和/或活性）和/或C5a过敏毒素介导的炎症（例如，C5a介导的炎性免疫细胞趋化性）。因此，双特异性抗体可用于治疗各种补体途径相关疾病的方法。

2. 发明申请

WO2007070538A9 ANTI-MN ANTIBODIES AND METHODS OF USING SAME 审中-公开
标题翻译：抗MN抗体及其使用方法
公开(公告)号：WO2007070538A9
公开(公告)日：2009-01-22
申请号：PCT/US2006047445
申请日：2006-12-12
申请人： BAYER HEALTHCARE LLC , TAMBURINI PAUL , RANGES GERALD , ADNANE LILA , MCCABE TIMOTHY , TRAIL PAMELA , HA SHA
发明人： TAMBURINI PAUL , RANGES GERALD , ADNANE LILA , MCCABE TIMOTHY , TRAIL PAMELA , HA SHA
IPC分类号： C12N5/02
CPC分类号： C07K16/40 , A61K39/395 , A61K47/6803 , A61K47/6817 , A61K47/6851 , A61K47/6871 , A61K2039/505 , C07K16/30 , C07K2317/21 , C07K2317/55 , C07K2317/565 , C07K2317/732 , C07K2317/77 , C07K2317/92 , A61K2300/00

3. 发明申请

WO1995013084A1 CATHEPSIN D IS AN AMYLOIDOGENIC PROTEASE IN ALZHEIMER'S DISEASE 审中-公开
标题翻译： CATHEPSIN D是阿尔茨海默病中的氨基酸分泌蛋白
公开(公告)号：WO1995013084A1
公开(公告)日：1995-05-18
申请号：PCT/US1994007043
申请日：1994-06-21
申请人： MILES INC. , TAMBURINI, Paul, Perry , BENZ, Günter, Hans, Heinz, Herbert , HÄBICH, Dieter , DREYER, Robert, Norman , KOENIG, Gerhard
发明人： MILES INC.
IPC分类号： A61K37/64
CPC分类号： C12N9/6478 , A61K38/00 , C07K14/4711 , C07K14/8142 , C07K16/18 , G01N33/6896 , G01N2333/4709 , G01N2333/8142 , G01N2333/96472
摘要： Deposition of the neurotoxic beta-amyloid peptide is a pathologic process that takes place in the brains of Alzheimer's disease patients. Disclosed are methods for treating a patient with a therapeutic compound that functions by blocking the formation of beta-amyloid from the amyloid precursor protein (APP). We have identified the aspartic protease cathepsin D as a protease responsible for amyloidogenic processing of APP. Non-toxic compounds are disclosed that block both the in vitro activity of human cathepsin D, and the release of beta-amyloid by human cells. Such aspartic protease inhibitors thus have utility as therapeutics for Alzheimer's disease by blocking the pathologic accumulation of beta-amyloid.
摘要翻译：神经毒性β-淀粉样蛋白肽的沉积是在阿尔茨海默病患者的大脑中发生的病理过程。公开了用于通过阻断淀粉样蛋白前体蛋白（APP）形成β-淀粉样蛋白而起作用的治疗化合物治疗患者的方法。我们已经鉴定出天冬氨酸蛋白酶组织蛋白酶D作为负责APP淀粉样生长加工的蛋白酶。公开了阻止人组织蛋白酶D的体外活性和人细胞释放β-淀粉样蛋白的无毒化合物。因此，这种天冬氨酸蛋白酶抑制剂因此通过阻断β-淀粉样蛋白的病理性积累而用作阿尔茨海默病的治疗剂。

4. 发明申请

WO2011137395A1 ANTI-C5A ANTIBODIES AND METHODS FOR USING THE ANTIBODIES 审中-公开
标题翻译：抗C5A抗体和使用抗体的方法
公开(公告)号：WO2011137395A1
公开(公告)日：2011-11-03
申请号：PCT/US2011/034672
申请日：2011-04-29
申请人： ROTHER, Russell, P. , SHERIDAN, Douglas, L. , TAMBURINI, Paul, P. , ZHANG, Yuchun
发明人： ROTHER, Russell, P. , SHERIDAN, Douglas, L. , TAMBURINI, Paul, P. , ZHANG, Yuchun
IPC分类号： C07K16/18
CPC分类号： C07K16/18 , A61K39/3955 , A61K45/06 , A61K47/60 , A61K2039/505 , C07K16/28 , C07K16/461 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/41 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.
摘要翻译：本公开尤其涉及结合C5a的抗体或其抗原结合片段以及在用于治疗或预防补体相关病症例如但不限于非典型溶血性尿毒症综合征的方法中使用抗体，年龄相关性黄斑变性，类风湿性关节炎，败血症，严重烧伤，抗磷脂脂质综合征，哮喘，狼疮肾炎，古德帕斯彻综合征和慢性阻塞性肺疾病。

5. 发明申请

WO2011137362A1 ANTIBODIES HAVING REDUCED IMMUNOGENICITY IN A HUMAN 审中-公开
标题翻译：具有降低人类免疫球蛋白的抗体
公开(公告)号：WO2011137362A1
公开(公告)日：2011-11-03
申请号：PCT/US2011/034598
申请日：2011-04-29
申请人： ROTHER, Russell, P. , TAMBURINI, Paul, P.
发明人： ROTHER, Russell, P. , TAMBURINI, Paul, P.
IPC分类号： C07K16/18
CPC分类号： C07K16/18 , C07K2317/24
摘要： The disclosure relates to engineered antibodies that when administered to a human, exhibit a low level of immunogenicity in the human. The disclosure also relates to methods for generating the antibodies. The engineered antibodies can be derived from, e.g. , non-human ( e.g. , murine) donor antibodies or from chimeric or humanized antibodies that, when chronically administered to a human, are known to, are predicted to, or are expected to, elicit a neutralizing anti-antibody response in the human.
摘要翻译：本公开涉及工程化的抗体，当被施用于人时，在人体中表现出低水平的免疫原性。本公开还涉及产生抗体的方法。工程化抗体可以衍生自例如非人（例如，鼠）供体抗体或来自嵌合或人源化抗体，当长期施用于人时，已被预测或预计会引起中和抗体在人体中的反应。

6. 发明申请

WO2010065520A1 METHODS FOR PREPARING AEROLYSIN POLYPEPTIDES OR CONJUGATES THEREOF 审中-公开
标题翻译：制备α-干扰素多肽或其结合物的方法
公开(公告)号：WO2010065520A1
公开(公告)日：2010-06-10
申请号：PCT/US2009/066223
申请日：2009-12-01
申请人： ALEXION PHARMACEUTICALS, INC. , TAMBURINI, Paul , JOHNSON, Krista , FAAS MCKNIGHT, Susan , COFIELL, Roxanne
发明人： TAMBURINI, Paul , JOHNSON, Krista , FAAS MCKNIGHT, Susan , COFIELL, Roxanne
IPC分类号： C07K1/14 , C07K14/195 , C12Q1/02 , G01N33/53
CPC分类号： G01N33/56911 , A61K47/558 , C07K14/195 , G01N2333/195 , G01N2800/22
摘要： The present disclosure relates to simplified and improved methods for preparing aerolysin polypeptides (e.g., non-lytic variant aerolysin polypeptides), or conjugates thereof, and to use of the polypeptides and conjugates. The methods for preparation include, e.g., methods for purifying aerolysin polypeptides from a sample and methods for conjugating a heterologous moiety (e.g., a detectable label) to the polypeptides.
摘要翻译：本公开涉及简化和改进的方法，用于制备嗜水溶菌素多肽（例如，非溶解变体溶血素多肽）或其缀合物，以及多肽和缀合物的用途。制备方法包括例如用于从样品纯化嗜水溶菌素多肽的方法和将异源部分（例如，可检测标记）缀合到多肽的方法。

7. 发明申请

WO1994013319A1 CATHEPSIN D IS AN AMYLOIDOGENIC PROTEASE IN ALZHEIMER'S DISEASE 审中-公开
标题翻译： CATHEPSIN D是阿尔茨海默病中的氨基酸分泌蛋白
公开(公告)号：WO1994013319A1
公开(公告)日：1994-06-23
申请号：PCT/US1993010889
申请日：1993-11-12
申请人： MILES INC. , TAMBURINI, Paul, Perry , BENZ, Günter, Hans, Heinz, Herbert , HÄBICH, Dieter , DREYER, Robert, Norman
发明人： MILES INC.
IPC分类号： A61K37/64
CPC分类号： C12N9/6478 , A61K38/55 , C07K14/4711 , C12Q1/37 , G01N33/6896 , G01N2333/4709 , G01N2333/8142 , G01N2333/96472 , G01N2800/2821
摘要： Disclosed are methods for regulating formation of beta-amyloid protein with inhibitors of proteases specific for the Precursor to the Alzheimer's Disease beta-amyloid protein, such as inhibitors of aspartic protease, cathepsin D, and a chymotryptic-like serine protease; a method for detecting in vitro protease activity for molecules which possess specificity necessary for the degradation of the Amyloid Precursor Protein; assays for identifying inhibitors of proteases specific for the Amyloid Precursor Protein; and identified inhibitors and their use as therapeutics for the treatment of Alzheimer's Disease.
摘要翻译：公开了调节β-淀粉样蛋白形成的方法，其具有对阿尔茨海默氏病前体β-淀粉样蛋白前体特异性蛋白酶的抑制剂，例如天冬氨酸蛋白酶，组织蛋白酶D和糜蛋白酶样丝氨酸蛋白酶的抑制剂; 用于检测具有淀粉样蛋白前体蛋白降解所必需的特异性的分子的体外蛋白酶活性的方法; 用于鉴定淀粉样前体蛋白特异性蛋白酶抑制剂的测定法; 并鉴定了抑制剂及其作为治疗阿尔茨海默病的治疗剂的用途。

8. 发明申请

WO9733996A2 HUMAN BIKUNIN 审中-公开
标题翻译：人类BIKUNIN
公开(公告)号：WO9733996A2
公开(公告)日：1997-09-18
申请号：PCT/US9703894
申请日：1997-03-10
申请人： BAYER AG , TAMBURINI PAUL P , DAVIS GARY , DELARIA KATHERINE A , MARLOR CHRISTOPHER W , MULLER DANIEL K
发明人： TAMBURINI PAUL P , DAVIS GARY , DELARIA KATHERINE A , MARLOR CHRISTOPHER W , MULLER DANIEL K
IPC分类号： A61P7/00 , A61K38/00 , A61K38/55 , A61P7/02 , A61P9/00 , A61P9/10 , A61P25/00 , A61P25/28 , A61P29/00 , A61P31/04 , A61P35/00 , A61P35/04 , A61P43/00 , C07K14/47 , C07K14/81 , C12N9/99 , C12N15/00 , C12N15/09 , C12N15/15 , C12P21/02 , A61K38/57
CPC分类号： C07K14/8117 , A61K38/00 , C07K14/8114
摘要： The instant invention provides for proteins, polypeptides, nucleic acid sequences, constructs, expression vectors, host cells, pharmaceutical compositions of, and methods for using human placental bikunin, serine protease inhibitor domains, and fragments thereof.
摘要翻译：本发明提供了用于使用人胎盘bikunin，丝氨酸蛋白酶抑制剂结构域和其片段的蛋白质，多肽，核酸序列，构建体，表达载体，宿主细胞，药物组合物和方法。

9. 发明申请

WO2014047500A1 SCREENING ASSAYS FOR COMPLEMENT COMPONENT C5 ANTAGONISTS 审中-公开
标题翻译：补充组件C5 ANTAGONISTS的筛选测试
公开(公告)号：WO2014047500A1
公开(公告)日：2014-03-27
申请号：PCT/US2013/061019
申请日：2013-09-20
申请人： ALEXION PHARMACEUTICALS, INC. , TAMBURINI, Paul, P.
发明人： TAMBURINI, Paul, P.
IPC分类号： G01N33/50 , G01N33/53 , G01N33/68
CPC分类号： G01N33/564 , G01N2333/4716 , G01N2500/04
摘要： Disclosed herein are compositions and methods for screening for novel compounds that bind to polypeptides of therapeutic interest (e.g., polypeptides implicated in, or known to contribute to, the pathogenesis of human disease). In some embodiments, the compounds bind to a component of the human complement cascade such as human complement component C5. In some embodiments, the compounds so identified inhibit complement- mediated activity and are potential drug candidates for treating complement-associated disorders. This disclosure also provides compositions and methods for screening for novel compounds that inhibit complement-mediated activity and may be useful for identifying potential drug candidates for treating patients showing little or no response to the existing therapies for treating complement associated disorders.
摘要翻译：本文公开了用于筛选结合治疗感兴趣的多肽的新化合物的组合物和方法（例如涉及或已知有助于人类疾病发病机理的多肽）。在一些实施方案中，化合物结合人补体级联的组分，例如人补体成分C5。在一些实施方案中，如此鉴定的化合物抑制补体介导的活性，并且是治疗补体相关疾病的潜在药物候选物。本公开还提供了用于筛选抑制补体介导的活性的新化合物的组合物和方法，并且可用于鉴定潜在的药物候选物，用于治疗对现有治疗补体相关疾病的治疗显示很少或没有反应的患者。

10. 发明申请

WO2007070538A2 ANTI-MN ANTIBODIES AND METHODS OF USING SAME 审中-公开
标题翻译：抗MN抗体及其使用方法
公开(公告)号：WO2007070538A2
公开(公告)日：2007-06-21
申请号：PCT/US2006/047445
申请日：2006-12-12
申请人： BAYER PHARMACEUTICALS CORPORATION , TAMBURINI, Paul , RANGES, Gerald , ADNANE, Lila , MCCABE, Timothy , TRAIL, Pamela
发明人： TAMBURINI, Paul , RANGES, Gerald , ADNANE, Lila , MCCABE, Timothy , TRAIL, Pamela
IPC分类号： C07K16/28 , A61K39/395
CPC分类号： C07K16/40 , A61K39/395 , A61K47/6803 , A61K47/6817 , A61K47/6851 , A61K47/6871 , A61K2039/505 , C07K16/30 , C07K2317/21 , C07K2317/55 , C07K2317/565 , C07K2317/732 , C07K2317/77 , C07K2317/92 , A61K2300/00
摘要： The invention provides antibodies having an antigenic binding site specifically directed against an MN protein, and methods for using such antibodies in treating and diagnosing an MN-related disorder.
摘要翻译：本发明提供具有针对MN蛋白特异性抗原结合位点的抗体，以及使用这些抗体治疗和诊断MN相关病症的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式